|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Differences in absolute levels of PTH and tumour weight suggest that renal HPT may be a confounding factor.
|
29497805 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
MEN1 is caused by abnormalities of the MEN1 gene which encodes a tumour suppressor; MEN2 and MEN3 are due to mutations of the rearranged during transfection (RET) proto-oncogene, which encodes a tyrosine kinase receptor; MEN4 is due to mutations of a cyclin-dependent kinase inhibitor (CDNK1B); and HPT-JT is due to mutations of cell division cycle 73 (CDC73), which encodes parafibromin.
|
27306766 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The risk of parathyroid carcinoma is elevated in patients with HPT-JT, necessitating rapid treatment and complete tumor resection to reduce the morbidity and mortality associated with intractable hypercalcemia due to local recurrence or metastatic disease.
|
22302605 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Heterozygous germline CDC73 mutations are detected in the majority of patients with HPT-JT, and the demonstration of loss of heterozygosity (LOH) at the CDC73 locus in tumors from affected individuals is consistent with a tumor suppressor role.
|
20052758 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is characterized by familial HPT, ossifying jaw tumors, and other associated neoplasms.
|
19529956 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HPT-JT and FIHP patients had similar laboratory, clinical, and demographic features and shared primary HPT and other neoplasms, the most common of which was uterine polyposis.
|
18755853 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
"Two-hits" (double mutations or one mutation and loss of heterozygosity at 1q24-32) affecting HRPT2 were found in two sporadic carcinomas, two HPT-JT-related and two FIHP related tumours.
|
12960210 |
2003 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings suggest that HRPT2 is a tumor-suppressor gene, the inactivation of which is directly involved in predisposition to HPT-JT and in development of some sporadic parathyroid tumors.
|
12434154 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Clonal analysis has shown that in renal hyperparathyroidism (2-HPT), parathyroid glands initially grow diffusely and polyclonally after which the foci of nodular hyperplasia are transformed to monoclonal neoplasia.
|
10048455 |
1999 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Whether it is a separate entity or a variant of multiple endocrine neoplasia type 1 (MEN1 at 11q13) or hyperparathyroidism-jaw tumor (HPT-JT or HRPT2 at 1q21-32) syndrome is not known.
|
9626148 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, we studied 29 patients with FBH from 11 families, 29 age- and sex-matched controls, and 42 patients with primary hyperparathyroidism (1 degree HPT), measuring PTH with a highly sensitive two-site immunochemiluminometric assay and the hypercalcemic tumor factor PTH-related peptide (PTHrP) with an extraction/concentration RIA.
|
1997510 |
1991 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Hypoparathyroidism can cause hypocalcemia and hyperphosphatemia, whereas deficient vitamin D actions can cause osteomalacia in adults and rickets in children.
|
28939209 |
2019 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Hypoparathyroidism is a rare endocrine disorder where deficiency (or lack of effect) of parathyroid hormone results in disordered mineral metabolism leading to hypocalcemia and hyperphosphatemia.
|
30261328 |
2019 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Hypoparathyroidism is a rare endocrine disorder characterized by low or insufficient parathyroid hormone (PTH) concentrations leading to hypocalcemia, hyperphosphatemia, and markedly reduced bone turnover.
|
31107289 |
2019 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Children are at a High Risk of Hypocalcaemia and Hypoparathyroidism after Total Thyroidectomy.
|
31383578 |
2019 |
|
Hyperparathyroidism, Primary
|
0.090 |
Biomarker
|
disease |
BEFREE |
HPT-JT is characterized by PHPT, ossifying fibromas of maxillary bones, kidney disease, and uterine neoplasias.
|
30641519 |
2019 |
|
Hyperparathyroidism, Primary
|
0.090 |
Biomarker
|
disease |
BEFREE |
Rates of persistence/recurrence did not significantly differ due to type of surgery (bilateral/unilateral) or type of HPT (spHPT/LIHPT/MEN).
|
31412376 |
2019 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Hypoparathyroidism is a rare disease characterized by hypocalcemia, hyperphosphatemia and a low or inappropriately normal serum parathyroid hormone level (PTH).
|
30540559 |
2018 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Hypoparathyroidism is characterised by hypocalcaemia, and standard management is with an active vitamin D analogue and adequate oral calcium intake (dietary and/or supplements).
|
28993435 |
2017 |
|
Hyperparathyroidism, Primary
|
0.090 |
Biomarker
|
disease |
BEFREE |
HPT-JT is a rare condition characterized by PHPT and benign tumors of the mandible and maxilla.
|
23757631 |
2014 |
|
Hypocalcemia
|
0.090 |
Biomarker
|
phenotype |
BEFREE |
Hypoparathyroidism and/or hypocalcemia are not clear etiological factors for enamel disturbances and there were no major correlations between medical conditions and enamel disturbances.
|
22070626 |
2012 |
|
Hypocalcemia
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Hypoparathyroidism is an abnormality of calcium metabolism characterized by low serum levels of parathyroid hormone in spite of hypocalcemia.
|
20119591 |
2010 |
|
Hyperparathyroidism, Primary
|
0.090 |
Biomarker
|
disease |
BEFREE |
The pathogenesis of primary hyperparathyroidism (I degrees -HPT) and secondary hyperparathyroidism (II degrees -HPT) remains to be elucidated.
|
19194773 |
2009 |
|
Hyperparathyroidism, Primary
|
0.090 |
Biomarker
|
disease |
BEFREE |
beta-Catenin was accumulated in all analyzed parathyroid tumors (n = 47) from patients with pHPT and from patients with HPT secondary to uremia.
|
17047023 |
2007 |
|
Hyperparathyroidism, Primary
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, a limited study of 28 primary hyperparathyroidism (pHPT) patients displayed a tendency of NciI influence on HPT development.
|
11902820 |
2001 |